Pritelivir

EQS-News: AiCuris Received 30 Million Euros Milestone Payment from Licensing Partner MSD Following U.S. FDA Approval of PREVYMIS® (letermovir) in Second Indication

Retrieved on: 
Wednesday, August 23, 2023

AiCuris Received 30 Million Euros Milestone Payment from Licensing Partner MSD Following U.S. FDA Approval of PREVYMIS® (letermovir) in Second Indication

Key Points: 
  • AiCuris Received 30 Million Euros Milestone Payment from Licensing Partner MSD Following U.S. FDA Approval of PREVYMIS® (letermovir) in Second Indication
    The issuer is solely responsible for the content of this announcement.
  • “We are excited that our partner MSD received FDA approval for PREVYMIS® (letermovir) for the prophylaxis of CMV infection in kidney transplanted patients.
  • Since 2017, the drug has already protected thousands of allogeneic stem cell transplanted patients from CMV disease.
  • With this label expansion, CMV-seropositive kidney transplant patients now have a novel, safe and effective treatment option,” said Larry Edwards, CEO of AiCuris Anti-infective Cures AG.

EQS-News: AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives for Immunocompromised Patients

Retrieved on: 
Thursday, July 6, 2023

AiCuris to continue its transition into a fully integrated biopharmaceutical company leveraging its research, clinical development, and commercialization expertise.

Key Points: 
  • AiCuris to continue its transition into a fully integrated biopharmaceutical company leveraging its research, clinical development, and commercialization expertise.
  • With AiCuris’ enhanced focus on development and commercialization of anti-infectives for immunocompromised individuals, the Company will discontinue research activities outside of this strategic scope.
  • Larry Edwards, CEO of AiCuris Anti-infective Cures AG, said: “Immunocompromised patients develop severe, partially life-threatening disease from infections that are typically well controlled in immune competent individuals.
  • Highly prevalent latent virus infections such as CMV, HSV and BKV can cause severe complications in immunocompromised patients for example, after transplantations.

EQS-News: AiCuris AG Announces Appointment of Larry Edwards as Chief Executive Officer and Formation of U.S. Subsidiary

Retrieved on: 
Saturday, April 15, 2023

AiCuris AG Announces Appointment of Larry Edwards as Chief Executive Officer and Formation of U.S. Subsidiary

Key Points: 
  • AiCuris AG Announces Appointment of Larry Edwards as Chief Executive Officer and Formation of U.S. Subsidiary
    The issuer is solely responsible for the content of this announcement.
  • He joins with excellent leadership capabilities and will be responsible for driving AiCuris’ growth strategy as well as managing its overall operations.
  • Mr. Edwards will also be President of the Company’s newly formed subsidiary, AiCuris U.S. Inc., located in Massachusetts.
  • Larry Edwards, newly appointed CEO of AiCuris, commented: “I very much look forward to working with the AiCuris team and leading the Company into an exciting future.

DGAP-News: AiCuris nominates team of researchers from the Universitätsklinikum Erlangen as one of the 2022 winners of AiCubator Resident Status, a corporate innovation accelerator initiative

Retrieved on: 
Thursday, September 8, 2022

AiCuris nominates team of researchers from the Universittsklinikum Erlangen as one of the 2022 winners of AiCubator Resident Status, a corporate innovation accelerator initiative

Key Points: 
  • AiCuris nominates team of researchers from the Universittsklinikum Erlangen as one of the 2022 winners of AiCubator Resident Status, a corporate innovation accelerator initiative
    The issuer is solely responsible for the content of this announcement.
  • We are excited to welcome Prof. Dr. Manfred Marschall and his team as one of the winners of the AiCubator Resident Status in 2022, said Dr. Holger Zimmermann, CEO of AiCuris Anti-infective Cures AG.
  • We are very much looking forward to working with the winning team and supporting them to advance their promising project to the next level.
  • We appreciate and feel honored that our project has been selected for the AiCubator program, said Prof. Dr. Manfred Marschall.

DGAP-News: AiCuris appoints experienced business leader Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer

Retrieved on: 
Thursday, September 1, 2022

AiCuris appoints experienced business leader Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer

Key Points: 
  • AiCuris appoints experienced business leader Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer
    The issuer is solely responsible for the content of this announcement.
  • AiCuris appoints experienced business leader Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer
    Wuppertal, Germany, September 1, 2022 - AiCuris Anti-infective Cures AG, a leading company in the discovery and development of drugs against infectious diseases, today announced the appointment of Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer (CFO), effective September 1, 2022.
  • Dr. Stefan Oschmann, Chairman of the Board of AiCuris, said: It is my pleasure to welcome Dr. Sabrina Kuttruff-Coqui as our new CFO.
  • Dr. Sabrina Kuttruff-Coqui, newly appointed CFO of AiCuris, commented: I am thrilled to join the AiCuris team at this crucial stage of development.

Global Genital Herpes Treatment Market Outlook Report 2022-2027 Featuring Key Vendors - GlaxoSmithKline, Glenmark Pharmaceuticals, Viatris, Novartis, Teva Pharmaceuticals, & Bausch Health Companies - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022

The "Genital Herpes Treatment Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genital Herpes Treatment Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global genital herpes treatment market is segmented based on drug type, distribution channel, virus type, route of administration, and geography.
  • HSV-2 is the leading virus type segment as HSV-2 is the leading cause of genital herpes.
  • North America is the major revenue contributor to the global genital herpes treatment market, with a share of more than 40%.

Genital Herpes Pipeline Insight Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, May 30, 2022

The "Genital Herpes - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genital Herpes - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This "Genital Herpes- Pipeline Insight, 2022" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Genital Herpes pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Genital Herpes R&D.
  • This segment of the report provides insights about the different Genital Herpes drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.

DGAP-News: AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus

Retrieved on: 
Wednesday, February 9, 2022

Under the terms of the agreement, AiCuris will gain exclusive rights to develop and commercialize Hybridize's BKV program, with focus on the treatment of BK virus-mediated nephropathy in renal transplant patients.

Key Points: 
  • Under the terms of the agreement, AiCuris will gain exclusive rights to develop and commercialize Hybridize's BKV program, with focus on the treatment of BK virus-mediated nephropathy in renal transplant patients.
  • Hybridize and AiCuris will collaborate in the further development of the BKV-targeting therapy until the start of clinical studies, which is expected within two years.
  • "BK virus is difficult to treat as it is not addressable using conventional approaches such as classical enzyme inhibitors.
  • Hybridize has merged these areas in its mission, focusing on helping patients overcome untreated kidney diseases with high unmet medical needs using RNA-based therapeutics.

Global Genital Herpes Pipeline Landscape Report 2021: Therapeutic Assessment by Product Type, Stage, Route of Administration, and Molecule Type - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 28, 2021

This Genital herpes - Pipeline Insight, 2021 provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Genital herpes pipeline landscape.

Key Points: 
  • This Genital herpes - Pipeline Insight, 2021 provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Genital herpes pipeline landscape.
  • It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Genital herpes R&D.
  • The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Genital herpes drugs.

DGAP-News: AiCuris received approval from BfArM to initiate Compassionate Use Program for Pritelivir in Germany

Retrieved on: 
Wednesday, December 2, 2020

"Especially in immunocompromised patients, HSV can lead to serious complications," said Dr. Holger Zimmermann, CEO of AiCuris.

Key Points: 
  • "Especially in immunocompromised patients, HSV can lead to serious complications," said Dr. Holger Zimmermann, CEO of AiCuris.
  • At the same time, the data collected in this program will help to bring the drug to patients as quickly as possible and support the planned approval of pritelivir."
  • The Compassionate Use Program in Germany is part of an Early Access Program (EAP) which is operated by myTomorrows, a Netherlands-based HealthTech company facilitating access to medicines in development and real-world data collection.
  • The EAP for treatment of acyclovir-resistant mucocutaneous HSV infections provides immunocompromised patients in different countries worldwide with pre-approval access to pritelivir.